Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 126

1.

Liver Stiffness Decreases Rapidly in Response to Successful Hepatitis C Treatment and Then Plateaus.

Chekuri S, Nickerson J, Bichoupan K, Sefcik R, Doobay K, Chang S, DelBello D, Harty A, Dieterich DT, Perumalswami PV, Branch AD.

PLoS One. 2016 Jul 21;11(7):e0159413. doi: 10.1371/journal.pone.0159413. eCollection 2016.

2.

Treatment of Chronic Hepatitis C in the Aged - Does It Impact Life Expectancy? A Decision Analysis.

Maor Y, Malnick SD, Melzer E, Leshno M.

PLoS One. 2016 Jul 13;11(7):e0157832. doi: 10.1371/journal.pone.0157832. eCollection 2016.

3.

Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon.

D'Ambrosio R, Degasperi E, Aghemo A, Fraquelli M, Lampertico P, Rumi MG, Facchetti F, Grassi E, Casazza G, Rosenberg W, Bedossa P, Colombo M.

PLoS One. 2016 Jun 15;11(6):e0155967. doi: 10.1371/journal.pone.0155967. eCollection 2016.

4.

Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.

Kanda T, Yasui S, Nakamura M, Suzuki E, Arai M, Haga Y, Sasaki R, Wu S, Nakamoto S, Imazeki F, Yokosuka O.

Int J Med Sci. 2016 May 12;13(6):418-23. doi: 10.7150/ijms.15519. eCollection 2016.

5.

The mitochondria-targeted antioxidant MitoQ attenuates liver fibrosis in mice.

Rehman H, Liu Q, Krishnasamy Y, Shi Z, Ramshesh VK, Haque K, Schnellmann RG, Murphy MP, Lemasters JJ, Rockey DC, Zhong Z.

Int J Physiol Pathophysiol Pharmacol. 2016 Apr 25;8(1):14-27. eCollection 2016.

6.

KASL clinical practice guidelines: management of hepatitis C.

Korean Association for the Study of the Liver.

Clin Mol Hepatol. 2016 Mar;22(1):76-139. doi: 10.3350/cmh.2016.22.1.76. Epub 2016 Mar 28. Review. No abstract available.

7.

Recent advances in managing chronic HCV infection: focus on therapy in patients with severe liver disease.

Maan R, van der Meer AJ.

F1000Res. 2016 Mar 17;5. pii: F1000 Faculty Rev-367. doi: 10.12688/f1000research.7399.1. eCollection 2016. Review.

8.

Increasing prevalence of cirrhosis among U.S. adults aware or unaware of their chronic hepatitis C virus infection.

Udompap P, Mannalithara A, Heo NY, Kim D, Kim WR.

J Hepatol. 2016 May;64(5):1027-32. doi: 10.1016/j.jhep.2016.01.009. Epub 2016 Jan 22.

9.

Chronic hepatitis C: This and the new era of treatment.

Bertino G, Ardiri A, Proiti M, Rigano G, Frazzetto E, Demma S, Ruggeri MI, Scuderi L, Malaguarnera G, Bertino N, Rapisarda V, Di Carlo I, Toro A, Salomone F, Malaguarnera M, Bertino E, Malaguarnera M.

World J Hepatol. 2016 Jan 18;8(2):92-106. doi: 10.4254/wjh.v8.i2.92. Review.

10.

Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity.

Poynard T, Deckmyn O, Munteanu M, Ngo Y, Drane F, Castille JM, Housset C, Ratziu V; FIBROFRANCE Group.

BMJ Open. 2015 Dec 23;5(12):e010017. doi: 10.1136/bmjopen-2015-010017.

11.

Effect of Treatment for CHC on Liver Disease Progression and Hepatocellular Carcinoma Development in African Americans.

Reddy N, Naylor P, Hakim Z, Asbahi R, Ravindran K, May E, Ehrinpreis M, Mutchnick M.

J Clin Transl Hepatol. 2015 Sep 28;3(3):163-8. doi: 10.14218/JCTH.2015.00013. Epub 2015 Sep 15.

12.

Kallistatin, a new and reliable biomarker for the diagnosis of liver cirrhosis.

Cheng Z, Lv Y, Pang S, Bai R, Wang M, Lin S, Xu T, Spalding D, Habib N, Xu R.

Acta Pharm Sin B. 2015 May;5(3):194-200. doi: 10.1016/j.apsb.2015.02.003. Epub 2015 Apr 7.

13.

Automated liver elasticity calculation for MR elastography.

Dzyubak B, Venkatesh SK, Manduca A, Glaser KJ, Ehman RL.

J Magn Reson Imaging. 2016 May;43(5):1055-63. doi: 10.1002/jmri.25072. Epub 2015 Oct 22.

PMID:
26494224
14.

Potential Role of the Gut/Liver/Lung Axis in Alcohol-Induced Tissue Pathology.

Massey VL, Beier JI, Ritzenthaler JD, Roman J, Arteel GE.

Biomolecules. 2015 Sep 30;5(4):2477-503. doi: 10.3390/biom5042477. Review.

15.

Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment.

Zuchowski JL, Hamilton AB, Pyne JM, Clark JA, Naik AD, Smith DL, Kanwal F.

BMC Gastroenterol. 2015 Oct 1;15:124. doi: 10.1186/s12876-015-0356-5.

16.

Effect of Peginterferon or Ribavirin Dosing on Efficacy of Therapy With Telaprevir in Treatment-Experienced Patients With Chronic Hepatitis C and Advanced Liver Fibrosis: A Multicenter Cohort Study.

Janczewska E, Flisiak R, Zarebska-Michaluk D, Kozielewicz D, Berak H, Dobracka B, Librant-Suska M, Lojewski W, Jurczyk K, Musialik J, Postawa-KlosiƄska B, Wroblewski J, Augustyniak K, Dudziak M, Olszok I, Ruszala A, Pisula A, Lapinski T, Kryczka W, Horban A, Dobracki W.

Medicine (Baltimore). 2015 Sep;94(38):e1411. doi: 10.1097/MD.0000000000001411.

17.

Changes of shear-wave velocity by interferon-based therapy in chronic hepatitis C.

Osakabe K, Ichino N, Nishikawa T, Sugiyama H, Kato M, Shibata A, Asada W, Kawabe N, Hashimoto S, Murao M, Nakano T, Shimazaki H, Kan T, Nakaoka K, Takagawa Y, Ohki M, Kurashita T, Takamura T, Yoshioka K.

World J Gastroenterol. 2015 Sep 21;21(35):10215-23. doi: 10.3748/wjg.v21.i35.10215.

18.

Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C.

Wu YJ, Xu MY, Lu LG.

J Clin Transl Hepatol. 2014 Dec;2(4):222-7. doi: 10.14218/JCTH.2014.00029. Epub 2014 Dec 15. Review.

19.

Hepatitis C: Treatment of difficult to treat patients.

Hilgenfeldt EG, Schlachterman A, Firpi RJ.

World J Hepatol. 2015 Jul 28;7(15):1953-63. doi: 10.4254/wjh.v7.i15.1953. Review.

20.

Hepatitis C cirrhosis: New perspectives for diagnosis and treatment.

Khullar V, Firpi RJ.

World J Hepatol. 2015 Jul 18;7(14):1843-55. doi: 10.4254/wjh.v7.i14.1843. Review.

Items per page

Supplemental Content

Write to the Help Desk